Pivotal kidneyintelX.dkd Data Published in Diabetes Care, Considered the Leading Clinical Journal Worldwide in Diabetes
Rhea-AI Summary
Aetna (CVS Health, NYSE: CVS) said its Aetna Clinical Collaboration (ACC) program is on track to be implemented in ten hospitals by year-end 2025, with rollouts underway at AdventHealth Shawnee Mission, Houston Methodist and WakeMed.
Early indicators show ~25% of enrolled members actively engaged with an Aetna care manager and the program is projected to reduce year-over-year 30-day readmissions and hospital length of stay by 5% when fully scaled. Aetna noted it serves > 4 million Medicare members aged 65+ and plans further ACC expansion in 2026, plus ACC for Commercial lines.
Positive
- Ten hospitals targeted for ACC implementation by end-2025
- ~25% member engagement with Aetna care managers in early rollout
- Projected 5% reduction in 30-day readmissions and length of stay
- >4 million Medicare members aged 65+ in Aetna's plan population
Negative
- Projected 5% reductions are not yet realized and remain forward-looking
- Near-term reach limited to ten hospitals (pilot-scale implementation)
New results and three presentations at ASN Kidney Week underscore kidneyintelX.dkd as a precision-medicine standard for CKD
The published manuscript, "Baseline Risk and Longitudinal Changes in kidneyintelX.dkd and Its Association with Kidney Outcomes in the CANVAS and CREDENCE Trials," was authored by leading nephrology and metabolism experts from the US,
Key Findings
-
Improved CKD risk prediction: kidneyintelX.dkd significantly enhanced risk stratification across all KDIGO guideline categories, delivering more accurate assessment of CKD progression risk and potential kidney failure.
- Actionable treatment guidance: Among patients classified as moderate or high risk, those treated with frontline SGLT2 inhibitors showed a significant reduction in kidneyintelX.dkd risk levels at one year, with high-risk patients twice as likely to show risk improvement compared with untreated patients.
The authors concluded that kidneyintelX.dkd, and its novel kidney biomarkers, enables clinicians to identify patients most likely to benefit from therapy, supporting personalized risk-based care today and offering a powerful tool for future clinical trials.
Expert Perspective
Associate Professor Brendon Neuen of The George Institute for Global Health,
"With multiple recent breakthroughs in therapies to reduce kidney function decline, the time for risk-based implementation in CKD has arrived. Incorporating novel biomarkers, as done with kidneyintelX.dkd, holds strong promise to guide risk-based care. These data provide a compelling example of how we can build on well-established clinical parameters to deliver more personalized care and reduce the risk of adverse outcomes."
Dr. Neuen serves as Program Lead, Renal & Metabolic at The George Institute and Director of Kidney Trials at Royal North Shore Hospital.
kidneyintelX.dkd Spotlighted in Three Presentations at ASN Kidney Week 2025
Renalytix also presented three new abstracts at ASN Kidney Week in
(Nov 5–9), highlighting real-world implementation, clinical utility, and performance advantages of kidneyintelX.dkd:
1. PO0330 — Implementation in a Large Integrated Health System
Demonstrated a scalable framework for deploying kidneyintelX.dkd to drive sustained population-level adoption and deliver personalized improvements in care management across a major US health network.
2. PO0331 — Decision-Impact Study in Community Practice
-
87% of patients reported better understanding of their kidney risk. -
98% said the test improved their understanding of kidney health and its importance. -
86% of physicians said kidneyintelX.dkd directly influenced care decisions.
3. PO0332 — Superior Prediction vs. KFRE
kidneyintelX.dkd outperformed the Kidney Failure Risk Equation (KFRE) in predicting kidney function decline or kidney failure in diabetic kidney disease, demonstrating superior discrimination and reliability, especially in early-stage disease.
Setting a New Standard in CKD Precision Medicine
Across clinical trials, real-world deployment, and head-to-head performance comparisons, kidneyintelX.dkd continues to show consistent, incremental value as a core component of precision medicine in CKD. These results support its role as a transformative tool in integrated care management—ultimately driving significant improvements in patient and health outcomes.
About Chronic Kidney Disease: a worldwide public health crisis
Chronic Kidney Disease is a worldwide public health crisis impacting 850 million individuals worldwide. According to the National Kidney Foundation, it is estimated to impact more than 35 million adults in
About Renalytix
Renalytix (LSE: RENX) (OTCQB: RNLXY) is an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes. Renalytix has received FDA approval and Medicare reimbursement for kidneyintelX.dkd which is now offered commercially in
To learn more about Renalytix, visit renalytix.com, and for information about the kidneyintelX.dkd test, visit kidneyintelx.com.
For further information, please contact:
|
Renalytix plc |
|
|
Elise Wilfinger |
ewilfinger@renalytix.com |
FAQ
What did Aetna announce about the ACC program implementation timeline?
How many Aetna members are eligible for the ACC program and when will it expand?
What engagement levels has Aetna reported for the ACC pilot program?
What clinical outcomes does Aetna project from ACC for Medicare members?
Which hospitals were named in Aetna's ACC rollout as of Sept 22, 2025?
Will Aetna deploy ACC for non-Medicare members?
